JCP
SAGE

Jabre Capital Partners’s Sage Therapeutics SAGE Stock Holding History

Jabre Capital Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,900
Closed -$410K – 85
2018
Q3 		$410K Buy
2,900
+600
+26% +$92.6K 0.14% 94
2018
Q2 		$360K Sell
2,300
-100
-4% -$15.7K 0.02% 138
2018
Q1 		$387K Buy
2,400
+500
+26% +$84.9K 0.08% 127
2017
Q4 		$313K Sell
1,900
-4,100
-68% -$398K 0.06% 84
2017
Q3 		$374K Buy
6,000
+2,000
+50% +$157K 0.07% 86
2017
Q2 		$319K Sell
4,000
-18,000
-82% -$1.3M 0.03% 104
2017
Q1 		$1.56M Buy
+22,000
New +$1.29M 0.19% 91

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jabre Capital Partners's SAGE Position: Q4 2018 in Review

Jabre Capital Partners sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 2,900 shares — an estimated $410K sold.

Jabre Capital Partners first reported a position in SAGE in Q1 2017 and held it in 7 quarters. The position peaked at $1.56M in Q1 2017. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Jabre Capital Partners reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 2,900 Sage Therapeutics shares in Q4 2018, an estimated $410K.
  • Jabre Capital Partners first reported a position in Sage Therapeutics in Q1 2017 and held it in 7 quarters.
  • Jabre Capital Partners's Sage Therapeutics position peaked at $1.56M in Q1 2017.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.